We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+11.71%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$722M
AUM Growth
-$60.1M
Cap. Flow
-$97.7M
Cap. Flow %
-13.52%
Top 10 Hldgs %
77.92%
Holding
44
New
2
Increased
3
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$19.3M
2
SYRE icon
Spyre Therapeutics
SYRE
+$4M
3
MRUS
Merus
MRUS
+$2.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$685K
5
ARDX icon
Ardelyx
ARDX
+$96.1K

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$27M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$18.4M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$15.6M
4
ACOR
Acorda Therapeutics
ACOR
+$13.2M
5
CDTX
Cidara Therapeutics
CDTX
+$9.24M

Sector Composition

Rank Sector Weight
1 Healthcare 93.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$4.24M 0.59%
20,540
-38,171
-65% -$9.24M
AKTX
27
Akari Therapeutics
AKTX
$14.4M
$3.16M 0.44%
293
-29
-9% -$374K
SYRE icon
28
Spyre Therapeutics
SYRE
$8.5B
$2.54M 0.35%
+20,862
New +$4M
MRUS
29
DELISTED
Merus
MRUS
$1.9M 0.26%
+237,599
New +$2.08M
ZYNE
30
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$1.74M 0.24%
253,468
-253,723
-50% -$2.12M
ORKA
31
Oruka Therapeutics
ORKA
$5.31B
$1.63M 0.23%
2,605
-998
-28% -$739K
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$59K 0.01%
743
-14,382
-95% -$2.74M
ARMP icon
33
Armata Pharmaceuticals
ARMP
$168M
– –
-383
Closed -$211K
BPMC
34
DELISTED
Blueprint Medicines
BPMC
– –
-56,442
Closed -$1.02M
CHRS icon
35
Coherus Oncology
CHRS
$217M
– –
-1,272,048
Closed -$27M
COLL icon
36
Collegium Pharmaceutical
COLL
$1.18B
– –
-486,557
Closed -$8.83M
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
– –
-8,709
Closed -$7.24M
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-153,216
Closed -$2.56M
ACOR
39
DELISTED
Acorda Therapeutics
ACOR
– –
-4,151
Closed -$13.2M
AGTC
40
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-236,059
Closed -$3.3M
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-936,411
Closed -$18.4M
CPXX
42
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-1,414,114
Closed -$15.6M
NDRM
43
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-144,671
Closed -$2.04M
DSCI
44
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-81,239
Closed -$252K
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, RA Capital Management held 44 positions worth $722M, down 7.7% from $782M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

RA Capital Management withdrew a net $97.7M in Q2 2016, closing 12 positions and reducing 9 holdings. Its most notable exit was Coherus Oncology, an estimated $27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Spyre Therapeutics worth $2.54M.

  • RA Capital Management's largest Q2 2016 buy was Spyre Therapeutics: 20,862 shares worth $2.54M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q2 2016, an estimated $19.3M increase.
  • RA Capital Management's biggest Q2 2016 reduction was Cidara Therapeutics, cutting an estimated $9.24M.
  • RA Capital Management fully exited Coherus Oncology in Q2 2016, selling an estimated $27M.
  • RA Capital Management's ten largest holdings make up 78% of its $722M portfolio in Q2 2016.
  • RA Capital Management opened 2 new positions and closed 12 in Q2 2016.
  • RA Capital Management's portfolio value fell 7.7% quarter-over-quarter to $722M.

Based on RA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.